Dr. John Houston: Attacking Disease by Targeting Proteins

Talking Biotech with Dr. Kevin Folta

Many diseases are rooted in the incorrect accumulation of proteins that regulate key cellular processes. Dozens of proteins control processes like cell division and cell death, and aberrant accumulation of these regulatory molecules can have profound health impacts. The Arvinas company has developed a means to specifically target specific proteins for degradation, exploiting a system called ubiqitination. Ubiqutin is a small molecular tag that sentences tagged proteins for degradation. Dr. John Houston is the CEO of Arvinas, and he describes the company’s progress in this exciting area of research and development. We discuss the technology, the progress, and the Arvinas pipeline. This alternative approach to controlling cellular processes holds great promise in the treatment of a number of human diseases.

www.Arvinas.com

# COLABRA
Talking Biotech is brought to you by Colabra – an R&D platform that brings your lab’s world-changing research together in one shared space. Learn more at https://www.colabra.app/

# TALKING BIOTECH
Twitter: https://twitter.com/talkingbiotech
Website: https://www.colabra.app/podcasts/talking-biotech/
Instagram: https://www.instagram.com/colabrahq

The Talking Biotech podcast is distinct from Dr. Kevin Folta's teaching and research roles at the University of Florida. The views expressed on the show are those of Dr. Folta and his guests, and do not reflect the opinions of the university or Colabra.